Newsroom | 48627 results
Sorted by: Latest
-
Samenvatting: Owkin maakt internationale validatieresultaten bekend van BRCAura: AI-gestuurde screening op gBRCA-mutaties rechtstreeks vanuit pathologische dia's
PARIJS--(BUSINESS WIRE)--Owkin deelt veelbelovende validatieresultaten voor BRCAura RUO, een AI-product van klinische kwaliteit dat uitsluitend voor onderzoeksdoeleinden. Het is bedoeld en ontworpen om direct vanuit gedigitaliseerde pathologische dia's van borstkanker te screenen op kiembaanmutaties van BRCA1/2 (gBRCAm). Borstkanker blijft wereldwijd de belangrijkste oorzaak van kankergerelateerde sterfgevallen onder vrouwen. Het in kaart brengen van patiënten met kiembaanmutaties in BRCA1/2 is...
-
Resumen: Owkin anuncia los resultados de la validación internacional de BRCAura: cribado con tecnología de IA para detectar mutaciones gBRCA directamente a partir de muestras patológicas
PARÍS--(BUSINESS WIRE)--Owkin comparte los prometedores resultados de la validación de BRCAura RUO, un producto de IA de grado clínico diseñado exclusivamente para la investigación y destinado a detectar mutaciones germinales BRCA1/2 (gBRCAm) directamente a partir de muestras digitalizadas de patología del cáncer de mama. El cáncer de mama sigue siendo la principal causa de muerte por cáncer de las mujeres de todo el mundo. Identificar a las pacientes con mutaciones germinales en los genes BRCA...
-
Owkin gibt internationale Validierungsergebnisse für BRCAura bekannt: KI-gestütztes Screening auf gBRCA-Mutationen direkt aus pathologischen Präparaten
PARIS--(BUSINESS WIRE)--Owkin veröffentlicht vielversprechende Validierungsergebnisse für BRCAura RUO, ein KI-Produkt in klinischer Qualität, das ausschließlich für Forschungszwecke bestimmt ist und zum Screening auf Keimbahn-BRCA1/2-Mutationen (gBRCAm) direkt aus digitalisierten pathologischen Präparaten von Brustkrebs entwickelt wurde. Brustkrebs ist nach wie vor die häufigste krebsbedingte Todesursache bei Frauen weltweit. Die Identifizierung von Patientinnen mit Keimbahn-BRCA1/2-Mutationen...
-
Vycellix Prepares for First-in-Human Study of Novel Allogeneic Cell Therapy Powered by Its Universal Cell Engineering Platform
BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)--Vycellix advancing breakthrough discovery to human study with aim to redefine paradigm for transplant medicines, eliminating risk of graft rejection....
-
Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers Publish Groundbreaking Study with 1,364 Whole-Genomes of Breast Cancer in Nature
SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--A research consortium led by Samsung Medical Center, Seoul St. Mary’s Hospital and bioinformatics partner Inocras Inc. has published the most comprehensive whole-genome breast cancer study of its kind in Nature. Using Inocras’s proprietary whole-genome analysis platform CancerVision™, the team analyzed 1,364 breast cancer genomes, together with transcriptomic data and matched clinical records. With more than 10.9 million somatic mutations mapped,...
-
Oligonucleotide Synthesis Market Industry Trends and Global Forecasts Report 2025-2035: Market Strengthens With 110+ Providers, North America Leads, Clinical Pipeline Exceeds 300 Trials - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: By Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users, Company Size and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering. The global oligonucleotide synthesis market is estimated to grow from USD 4.8 billion in 2025, to USD 13.5 billion by 2035, at a CAGR of 9.9% during th...
-
GXP-Storage Appoints Former Eli Lilly Global Clinical Research Executive Chris Otto to Board of Directors
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Chris Otto brings over three decades of global clinical research experience to the Board of Directors of GXP-Storage....
-
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova’s purpose as a Comp...
-
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans...
-
Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a clinical-stage biopharmaceutical company pioneering next-generation T-cell engaging bispecific antibodies for solid tumors, today announced that the first patient has been dosed in its Phase 1/1b clinical trial evaluating RNDO-564, a first-in-class bispecific antibody targeting CD28 and Nectin-4, in adults with relapsed or refractory locally advanced or metastatic urothelial carcinoma (mUC) and other solid tumors associated with Nectin-4 e...
